- Home
- MSGS vs RDY Comparison
MSGS vs RDY Comparison
Compare MSGS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSGS | RDY |
|---|---|---|
| Founded | 1879 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 9.9B |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MSGS | RDY |
|---|---|---|
| Price | $416.35 | $13.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $480.67 | $13.83 |
| AVG Volume (30 Days) | 321.3K | ★ 2.8M |
| Earning Date | 11-03-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | ★ 134.41 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.76 |
| Revenue Next Year | $3.79 | $11.70 |
| P/E Ratio | $1,291.53 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $207.90 | $11.36 |
| 52 Week High | $438.93 | $15.67 |
Technical Indicators
Market Signals| Indicator | MSGS | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 65.19 |
| Support Level | $379.80 | $12.90 |
| Resistance Level | $420.06 | $13.54 |
| Average True Range (ATR) | 10.90 | 0.21 |
| MACD | 0.71 | 0.07 |
| Stochastic Oscillator | 93.23 | 87.50 |
Price Performance
Historical ComparisonAbout MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp is owns and operates a portfolio of assets featuring some of the recognized teams in all of sports, including the Knicks of the National Basketball Association (NBA) and the Rangers of the National Hockey League (NHL). The company has one operating and reportable segment.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.